Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Free Report) – Investment analysts at HC Wainwright increased their Q1 2025 earnings per share estimates for Dianthus Therapeutics in a research report issued to clients and investors on Wednesday, March 12th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($1.03) per share for the quarter, up from their prior forecast of ($1.21). HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q2 2025 earnings at ($1.10) EPS, Q3 2025 earnings at ($1.05) EPS, Q4 2025 earnings at ($0.89) EPS, FY2025 earnings at ($4.07) EPS and FY2026 earnings at ($4.60) EPS.
Other equities research analysts also recently issued reports about the company. Wedbush reiterated an “outperform” rating and issued a $36.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Guggenheim reiterated a “buy” rating and issued a $84.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, TD Cowen assumed coverage on Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating on the stock. Eight analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Dianthus Therapeutics presently has a consensus rating of “Buy” and an average price target of $52.14.
Dianthus Therapeutics Stock Performance
Shares of NASDAQ DNTH opened at $21.33 on Monday. The business’s 50 day moving average price is $22.54 and its 200-day moving average price is $24.81. Dianthus Therapeutics has a fifty-two week low of $18.13 and a fifty-two week high of $33.77. The company has a market cap of $631.30 million, a price-to-earnings ratio of -8.53 and a beta of 1.82.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last issued its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.04. Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.40 million.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the company. Quest Partners LLC boosted its position in Dianthus Therapeutics by 112,400.0% during the 3rd quarter. Quest Partners LLC now owns 1,125 shares of the company’s stock valued at $31,000 after acquiring an additional 1,124 shares in the last quarter. R Squared Ltd bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $26,000. KLP Kapitalforvaltning AS bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $33,000. KBC Group NV bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $35,000. Finally, BNP Paribas Financial Markets bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $59,000. Institutional investors own 47.53% of the company’s stock.
About Dianthus Therapeutics
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Read More
- Five stocks we like better than Dianthus Therapeutics
- Find and Profitably Trade Stocks at 52-Week Lows
- How to Build the Ultimate Everything ETF Portfolio
- How to Use the MarketBeat Stock Screener
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What Are the U.K. Market Holidays? How to Invest and Trade
- 3 Stocks With High ROE and Market-Beating Growth Potential
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.